Brit J Cancer:癌症骨转移患者预后如何 NLR和PLR能说明问题!

2018-10-27 吴星 环球医学网

骨转移是癌症患者的常见问题,手术决策的制定取决于多个因素,包括生命预期。新的预后因素的识别可改善生存期,并指导医生制定手术决策。2018年9月,发表在《Br J Cancer.》的一项研究旨在确定,中性粒细胞与淋巴细胞的比值(NLR)和血小板与淋巴细胞的比值(PLR)在骨转移患者中的预后价值。

骨转移是癌症患者的常见问题,手术决策的制定取决于多个因素,包括生命预期。新的预后因素的识别可改善生存期,并指导医生制定手术决策。2018年9月,发表在《Br J Cancer.》的一项研究旨在确定,中性粒细胞与淋巴细胞的比值(NLR)和血小板与淋巴细胞的比值(PLR)在骨转移患者中的预后价值。

2002~2014年,2家三级转诊中心的1012名患者符合纳入标准。双变量和多变量Cox回归分析,用于确定NLR和PLR与生存期之间的相关性。

3个月时,84.0%的低NLR患者存活,高NLR的患者有61.3%存活(P<0.001),对于PLR,低的患者为75.8%,高的为55.6%(P<0.001)。NLR和PLR升高都与较差的生存结局独立相关(风险比(HR)分别为,1.311和1.358;95% CI,1.117~1.538和1.152~1.601;P=0.001和P<0.001)。

研究表明,NLR和PLR都与接受治疗的骨转移患者生存期独立相关。

原始出处:
Thio QCBS1, Goudriaan WA2, Janssen SJ3, et al.Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases.Br J Cancer. 2018 Sep;119(6):737-743. doi: 10.1038/s41416-018-0231-6. Epub 2018 Aug 17.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1819967, encodeId=35e7181996e7b, content=<a href='/topic/show?id=4bf410018055' target=_blank style='color:#2F92EE;'>#预后如何#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100180, encryptionId=4bf410018055, topicName=预后如何)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Mar 03 05:30:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692016, encodeId=365f16920160f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Feb 12 12:30:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407749, encodeId=a3fe140e749f4, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Mon Oct 29 06:30:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350684, encodeId=335c35068428, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Oct 27 21:05:51 CST 2018, time=2018-10-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1819967, encodeId=35e7181996e7b, content=<a href='/topic/show?id=4bf410018055' target=_blank style='color:#2F92EE;'>#预后如何#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100180, encryptionId=4bf410018055, topicName=预后如何)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Mar 03 05:30:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692016, encodeId=365f16920160f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Feb 12 12:30:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407749, encodeId=a3fe140e749f4, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Mon Oct 29 06:30:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350684, encodeId=335c35068428, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Oct 27 21:05:51 CST 2018, time=2018-10-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1819967, encodeId=35e7181996e7b, content=<a href='/topic/show?id=4bf410018055' target=_blank style='color:#2F92EE;'>#预后如何#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100180, encryptionId=4bf410018055, topicName=预后如何)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Mar 03 05:30:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692016, encodeId=365f16920160f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Feb 12 12:30:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407749, encodeId=a3fe140e749f4, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Mon Oct 29 06:30:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350684, encodeId=335c35068428, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Oct 27 21:05:51 CST 2018, time=2018-10-27, status=1, ipAttribution=)]
    2018-10-29 yuandd
  4. [GetPortalCommentsPageByObjectIdResponse(id=1819967, encodeId=35e7181996e7b, content=<a href='/topic/show?id=4bf410018055' target=_blank style='color:#2F92EE;'>#预后如何#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100180, encryptionId=4bf410018055, topicName=预后如何)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Mar 03 05:30:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692016, encodeId=365f16920160f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Feb 12 12:30:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407749, encodeId=a3fe140e749f4, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Mon Oct 29 06:30:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350684, encodeId=335c35068428, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Oct 27 21:05:51 CST 2018, time=2018-10-27, status=1, ipAttribution=)]
    2018-10-27 医者仁心5538

    学习了

    0

相关资讯

Ann Intern Med:TNFi治疗是否增加RA患者的癌症复发风险?

2018年9月,瑞典学者在《Ann Intern Med》发表的一项全国基于人群的队列研究,考察了肿瘤坏死因子抑制剂(TNFi)与瑞典类风湿关节炎(RA)患者癌症复发之间的相关性。

Nat Commun:对年轻癌症患者进行全基因组测序势在必行

在最近的一项研究中,圣裘德儿童研究医院的科学家显示,将全基因组测序纳入临床基因组测试,可以在近一半的患者中发现更多的致癌基因突变。此举为临床基因组测试提供了一个新的黄金标准,并强调了将全基因组测序纳入儿科癌症患者临床测试和治疗的迫切需要。

JAMA Oncology:抵挡癌症年轻化,饮食、锻炼永远是主旋律

数据显示,虽然50岁及以上人群的结肠癌发病率有所下降,但年轻美国人的结肠癌发病率却在攀升。5月,美国癌症协会曾建议将结肠癌筛查年龄由先前的50岁提前至45岁。现在,一项新研究进一步表明, 20至49岁超重或肥胖的女性在50岁前患结肠癌的风险高达两倍!

赫捷院士:我国肿瘤防控网络已基本建成

目前我国癌谱呈现发展中国家和发达国家共存的现状,癌症防控形势严峻。

Brit J Cancer:腰围与23种部位特异性癌症风险的关种

由此可见,中心性肥胖与几种癌症的风险相关,并且独立于一般性肥胖。BMI介导作用的异质性表明不同的机制与不同的癌症部位相关。基于这些发现,应采取积极的策略来监测和预防中心性肥胖。

克利夫兰公布2019十大医学创新 所有癌症有望找到有效疗法

疼痛替代疗法、AI在医疗中的应用、卒中患者时间窗延长……这些创新在2019年将进一步“治愈”和改变医疗行业。当地时间10月24日,克利夫兰医学中心在其2018医疗创新峰会(2018 Medical Innovation Summit)上发布了“2019十大医学创新”。“医疗是千变万化的,我们预测像癌症免疫疗法和药物基因组学这样的创新,将给医疗领域带来巨大转变,改善克利夫兰医学中心乃至全世界患